Excellos
A unique full-service CDMO, setting new standards in Cell & Gene Therapy
A unique full-service CDMO, setting new standards in Cell & Gene Therapy
Excellos is a biotechnology startup based in the United States, founded in 2021. It operates as a unique full-service CDMO, focusing on cell and gene therapy innovation. Leveraging the expertise and resources of the San Diego Blood Bank with over 70 years of experience, Excellos aims to set a new industry standard. The company excels in collecting critical human cells and tissues and providing manufacturing and development services for the cell and gene therapy industry, with a specific focus on therapies in preclinical through phase II/III, and scalable operations for commercial use. Excellos' last investment was a $5.00M Venture Round investment on 16 August 2023. The company has been able to secure this investment without disclosing the specific investors. With its commitment to leveraging donor populations for life science research and advancing cellular therapies, Excellos is poised to contribute significantly to the healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | Unknown | 1 | Vitalant | 17 Jan 2024 |
| Venture Round | $5.00M | - | 16 Aug 2023 | |
| Funding Round | $15.00M | 1 |
|
25 Jan 2022 |
No recent news or press coverage available for Excellos.
We care about your data, and we'd love to use cookies make your experience better.
